Te Ahumairangi Investment Management Ltd Purchases New Position in Eli Lilly and Company $LLY

Te Ahumairangi Investment Management Ltd purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 3,120 shares of the company’s stock, valued at approximately $2,381,000.

Several other institutional investors have also modified their holdings of LLY. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Eli Lilly and Company by 19.0% during the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock worth $109,291,000 after purchasing an additional 22,410 shares in the last quarter. Schnieders Capital Management LLC. increased its position in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Finally, Jupiter Asset Management Ltd. lifted its holdings in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. Jupiter Asset Management Ltd. now owns 21,449 shares of the company’s stock valued at $16,720,000 after purchasing an additional 390 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY traded up $12.26 during mid-day trading on Friday, hitting $989.51. 614,389 shares of the company were exchanged, compared to its average volume of 3,156,544. The stock has a 50 day simple moving average of $1,039.17 and a 200-day simple moving average of $947.29. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a market cap of $934.91 billion, a price-to-earnings ratio of 43.15, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. During the same period in the previous year, the company posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Ratings Changes

LLY has been the subject of a number of research analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. HSBC reiterated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday. Guggenheim lifted their target price on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access expansion for tirzepatide drugs (Zepbound, Mounjaro) broadens insured demand and reduces out-of-pocket barriers, supporting near-term volume growth. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Large international capacity investments — most notably a $3B China manufacturing commitment plus separate Korea and Japan investments — reduce supply risk, support local pricing flexibility, and position Lilly to capture rapid GLP‑1 market growth in APAC. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Pipeline and commercial initiatives remain growth drivers: the company is filing/launching oral GLP‑1 orforglipron (mid‑2026 target) and promoting Employer Connect / LillyDirect to expand employer coverage — potential to materially increase addressable market and volumes if uptake continues. Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand
• Neutral Sentiment: Analyst and market narrative remains bullish on long‑term GLP‑1 dominance (strong buy calls, elevated price targets) even as management guides for slower but still robust EPS growth — supports long‑term thesis but keeps expectations high. Eli Lilly: The Weight-Loss Craze Isn’t Over
• Negative Sentiment: Safety/regulatory overhang — Lilly flagged a concerning unknown impurity in compounded (non‑commercial) tirzepatide mixed with vitamin B12; that warning could prompt tighter scrutiny of compounding practices and consumer caution, and generate negative headlines or enforcement actions. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Near-term market psychology and trading momentum concerns: some commentators warn the GLP‑1 euphoria and LLY’s price action have weakened since late 2025, raising risk of multiple compression or short‑term pullbacks despite solid fundamentals. Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.